Utama › Penyakit Neurologi › North Carolina
Kajian klinikal Penyakit Neurologi di North Carolina
7 kajian untuk Penyakit Neurologi sedang mencari peserta di lokasi di North Carolina.
Bandar di North Carolina
Teks kajian rasmi (Bahasa Inggeris)
A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence
- Denver, North Carolina, Denver
- Huntersville, North Carolina, Huntersville
Mengambil pesertaFasa 2/3
Umur 18 hingga 70 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT07598708Product Surveillance Registry
- Chapel Hill
- Charleston
- Durham
- dan 3 lagi
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 18 Sep 2026 · NCT01524276A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
- Research Site, Chapel Hill
Mengambil pesertaFasa 1
Umur 18 hingga 70 · Semua jantina · Dikemas kini 15 Sep 2026 · NCT06916806A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy
- Vima Site #067, Raleigh
Mengambil pesertaFasa 2
Umur 18 hingga 65 · Semua jantina · Dikemas kini 11 Sep 2026 · NCT07804615A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
- Duke University, Durham
Mengambil pesertaFasa 1
Umur 50 hingga 85 · Semua jantina · Dikemas kini 24 Ogo 2026 · NCT06297590Rett Syndrome Registry
- The University of North Carolina at Chapel Hill, Chapel Hill
Mengambil pesertaKajian pemerhatian
Umur 0 hingga 99 · Semua jantina · Dikemas kini 30 Jun 2026 · NCT05432349Open-label Extension Study in Participants With Early Alzheimer's Disease
- GSK Investigational Site, Matthews
Mengambil pesertaFasa 2
Umur 50 hingga 85 · Semua jantina · Dikemas kini 2 Feb 2026 · NCT07105709Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.